Main Street Financial Solutions LLC Decreases Stock Holdings in Merck & Co., Inc. $MRK

Main Street Financial Solutions LLC lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 19.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 25,500 shares of the company’s stock after selling 6,309 shares during the quarter. Main Street Financial Solutions LLC’s holdings in Merck & Co., Inc. were worth $2,684,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $25,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. in the fourth quarter worth about $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. in the third quarter worth about $31,000. Finally, High Note Wealth LLC lifted its stake in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 0.4%

Merck & Co., Inc. stock opened at $115.67 on Thursday. The stock has a 50-day moving average of $116.22 and a two-hundred day moving average of $113.53. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The stock has a market cap of $285.69 billion, a PE ratio of 32.58, a price-to-earnings-growth ratio of 2.59 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the business posted $2.22 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Wall Street Analyst Weigh In

MRK has been the subject of a number of research reports. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. UBS Group upped their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.